Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Hongkai Zhuang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4106-8736; OpenAlex author ID A5066540076. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2020: 6 papers · 2021: 6 papers · 2022: 4 papers · 2023: none · 2024: 1 paper

Papers 17

  1. LINC00909 up-regulates pluripotency factors and promotes cancer stemness and metastasis in pancreatic ductal adenocarcinoma by targeting SMAD4. Co-author DOI 10.1186/s13062-024-00463-4↗
  2. Identification of LIPH as an unfavorable biomarkers correlated with immune suppression or evasion in pancreatic cancer based on RNA-seq. Co-author DOI 10.1007/s00262-021-03019-x↗
  3. Identification by genetic algorithm optimized back propagation artificial neural network and validation of a four-gene signature for diagnosis and prognosis of… Co-author DOI 10.1016/j.heliyon.2022.e11321↗
  4. Identification of MBOAT2 as an Unfavorable Biomarker Correlated with KRAS Activation and Reduced CD8+ T-Cell Infiltration in Pancreatic Cancer. First author DOI 10.1155/2022/4269733↗
  5. ZMAT1 acts as a tumor suppressor in pancreatic ductal adenocarcinoma by inducing SIRT3/p53 signaling pathway. Co-author DOI 10.1186/s13046-022-02310-8↗
  6. Prognostic values and immune suppression of the S100A family in pancreatic cancer. Co-author DOI 10.1111/jcmm.16343↗
  7. Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2021/6682697↗
  8. Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer. Co-author DOI 10.1155/2021/9949272↗
  9. Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy. Co-author DOI 10.1177/11795549211024149↗
  10. CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. Co-author DOI 10.7150/jca.57082↗
  11. Prognostic stratification based on a novel nomogram for left-sided pancreatic adenocarcinoma after surgical resection: a multi-center study. Co-author PMID 34249426↗
  12. FAM83H overexpression predicts worse prognosis and correlates with less CD8+ T cells infiltration and Ras-PI3K-Akt-mTOR signaling pathway in pancreatic cancer. Co-author DOI 10.1007/s12094-020-02365-z↗
  13. GTF2IRD1 overexpression promotes tumor progression and correlates with less CD8+ T cells infiltration in pancreatic cancer. Co-author DOI 10.1042/bsr20202150↗
  14. Establishment of a 7-miRNA-Based Risk Score System for Predicting Prognosis of Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001542↗
  15. Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer. Co-author DOI 10.1111/jcmm.15990↗
  16. A four prognosis-associated lncRNAs (PALnc) based risk score system reflects immune cell infiltration and predicts patient survival in pancreatic cancer. Co-author DOI 10.1186/s12935-020-01588-y↗
  17. B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8+ T cells in pancreatic cancer. Co-author DOI 10.18632/aging.202255↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baohua Hou · 16 shared papers, 2020–2024 · strength 2.20
  2. Chuanzhao Zhang · 16 shared papers, 2020–2024 · strength 2.20
  3. Shanzhou Huang · 14 shared papers, 2020–2024 · strength 1.89
  4. Zuyi Ma · 14 shared papers, 2020–2024 · strength 1.82
  5. Zixuan Zhou · 14 shared papers, 2020–2024 · strength 1.82
  6. Zhenchong Li · 10 shared papers, 2020–2024 · strength 1.34
  7. Yuanfeng Gong · 5 shared papers, 2020–2021 · strength 0.60
  8. Qi Zhou · 3 shared papers, 2021–2024 · strength 0.45
  9. Bo Chen · 3 shared papers, 2021–2022 · strength 0.44
  10. Shujie Wang · 3 shared papers, 2021–2022 · strength 0.41
  11. Yiping Zou · 3 shared papers, 2021 · strength 0.34
  12. Bowen Huang · 3 shared papers, 2021 · strength 0.34
  13. Zelong Wu · 1 shared paper, 2024 · strength 0.18
  14. Junchao Guo · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.